Dysregulation of cholinergic neurotransmission through muscarinic receptors, particularly the M1 and M4 subtypes, has been implicated in the pathophysiology of schizophrenia. Muscarinic M4 receptor agonists and positive allosteric modulators (PAMs) have demonstrated the ability to modulate the disrupted neural circuits associated with this disorder.